Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
IDEAYA Biosciences, Inc. is a publicly traded biotechnology company focused on the discovery and development of targeted therapies for cancer, with an emphasis on precision medicine and synthetic lethality. The company operates within the biotechnology and oncology drug development industries, applying molecular diagnostics and genetic insights to identify patient populations most likely to benefit from its therapies. IDEAYA’s core strategy centers on exploiting cancer-specific genetic vulnerabilities, particularly within DNA damage repair and related pathways.
Founded in 2015, IDEAYA Biosciences has evolved from an early-stage research organization into a clinical-stage oncology company with multiple internally discovered programs in human clinical trials. Its differentiated positioning lies in the integration of computational biology, functional genomics, and medicinal chemistry to systematically identify and drug synthetic lethal targets. The company generates no material commercial revenue as of the latest public disclosures and is primarily funded through equity financing and strategic collaborations.
Business Operations
IDEAYA’s operations are organized around Precision Oncology Research and Development, encompassing target discovery, preclinical development, and clinical evaluation of small-molecule therapeutics. The company’s pipeline includes programs targeting molecularly defined cancers, such as tumors with specific genetic alterations in DNA damage response, chromatin regulation, and metabolic pathways. Revenue generation is primarily derived from collaboration and licensing agreements rather than product sales.
The company conducts its research and development activities mainly in the United States, supported by laboratory and clinical operations. IDEAYA controls proprietary discovery platforms and a portfolio of intellectual property supporting its drug candidates. It operates through wholly owned subsidiaries, though detailed subsidiary-level financial disclosures are limited in public filings. Strategic partnerships with larger pharmaceutical companies support select development programs and provide non-dilutive funding through upfront payments, milestones, and potential royalties.
Strategic Position & Investments
IDEAYA’s strategic direction emphasizes advancing a wholly owned clinical pipeline while selectively partnering assets to offset development risk and capital requirements. Growth initiatives focus on expanding its synthetic lethality platform, progressing multiple candidates through early- and mid-stage clinical trials, and leveraging biomarkers to enhance clinical success rates. The company has publicly highlighted its intent to maintain a balanced approach between internal development and external collaborations.
Notable strategic investments include multi-program collaborations with major pharmaceutical partners, including GlaxoSmithKline (GSK), centered on oncology targets such as MAT2A. IDEAYA has not completed large-scale corporate acquisitions but continues to invest heavily in emerging oncology targets, including DNA damage repair, cell cycle regulation, and tumor-specific metabolic dependencies. Some details regarding the long-term commercial scope of individual programs remain subject to clinical outcomes and partner decisions.
Geographic Footprint
IDEAYA Biosciences is headquartered in South San Francisco, California, a major global hub for biotechnology and life sciences. The company’s primary research, development, and corporate functions are based in the United States, with clinical trials conducted across multiple regions depending on study design and regulatory requirements.
While IDEAYA does not maintain extensive international commercial operations, its clinical development activities and strategic collaborations give it operational exposure to North America, Europe, and other regions involved in global oncology trials. Its geographic influence is primarily research- and development-oriented rather than sales-driven at this stage of its corporate lifecycle.
Leadership & Governance
IDEAYA was co-founded by industry veterans with backgrounds in oncology research and drug development. The leadership team emphasizes a science-driven culture focused on disciplined target validation, data-driven decision-making, and precision patient selection. Governance follows standard public-company practices, with oversight provided by an independent board of directors and adherence to U.S. securities regulations.
Key executives include:
- Yujiro S. Hata – President and Chief Executive Officer
- Igor Gorbatchev – Chief Financial Officer
- Margaret Grogan – Chief Scientific Officer
The executive team collectively brings experience from large pharmaceutical companies and successful biotechnology ventures, supporting IDEAYA’s long-term strategy of building a differentiated precision oncology pipeline while managing clinical and financial risk.